Since the advent of combination antiretroviral therapy Background (cART), non-AIDS defining malignancies (NADM) have become increasingly important. We examined risk factors for NADM, including immunological, virological and socio-behavioral characteristics.
prostate cancer (SIR 1.03, 0.76-1.38). Anal cancer was associated with low CD4 cell count, high CD8 cell count, men who have sex with men, and smoking. For lung cancer, the CD8 cell count was the only significant predictor identified among the immunological and virological factors. CD4 cell count, and chronic hepatitis B and C infection were predictive of liver cancer incidence. We found no evidence of any of the immunological factors being associated with prostate cancer.
The importance of immunodeficiency (indexed by CD4 Conclusions: count) and immune senescence (indexed by CD8 count) differs across NADM. Immunodeficiency was an important risk factor for anal and liver cancer whereas immune senescence was associated with lung cancer and anal cancer.
Keywords
Non-AIDS defining cancers, cohort studies, coinfection, hepatitis 
Introduction
In high-income countries, life expectancy of people living with HIV (PLWHIV) on combination antiretroviral therapy (cART) is approaching that of the general population 1 . For example, in Switzerland 2006 to 2013, PLWHIV with higher education had an estimated life expectancy similar to individuals from the general population with compulsory education 2 . Similarly, in Canada 2008 to 2012, life expectancy at age 20 years in HIV-positive people was 89% of the life expectancy in the general population 3 . In line with the increasing life expectancy, morbidity and mortality of PLWHIV on cART are no longer dominated by AIDS-defining events, but also affected by cardiovascular events and non-AIDS defining malignancies (NADM) [1] [2] [3] [4] [5] .
An analysis of causes of death in the Data collection on Adverse events of Anti-HIV Drugs (a collaboration of eleven HIV cohort studies from Europe, the USA and Australia), found that mortality decreased from 1999 to 2011 for most causes of death, including AIDS-related, liver-related, cardiovascular and other or unknown causes 4 . However, in this collaborative study 4 and in other cohorts 5-7 , mortality from NADM remained stable over time. This type of cancer is now the most common cause of non-AIDS deaths in PLWHIV in high-income countries 8 . Furthermore, compared to the general population, the incidence of NADM is increased in PLWHIV, with a standardized incidence ratio for all NADM combined ranging from 1.6 to 2.8 across different studies 9 .
Several factors contribute to the higher risk of NADM among HIV-positive individuals, including prolonged exposure to immunodeficiency, a higher prevalence of smoking, and infections with oncogenic viruses such as human papilloma virus (HPV) or hepatitis B (HBV) or hepatitis C (HCV) viruses 10-12 . Direct pro-oncogenic effects of HIV, inflammation, and coagulation pathways may also play a role 13,14 . More recently, accelerated immune senescence, as evidenced by low ratios of CD4 to CD8 positive T cells (CD4/CD8 ratio), has been identified as a potential risk factor for NADM 15, 16 . For example, in the US Veterans Aging Cohort Study, the CD4/CD8 ratio, but not the CD4 cell count, was an independent risk factor for lung cancer 15 .
We linked the database of the Swiss HIV Cohort Study (SHCS) with cantonal cancer registries to examine the relative importance of different risk factors for NADM, including immunological, virological and socio-behavioral factors.
Methods

The Swiss HIV Cohort Study
The SHCS is an ongoing observational study that promotes clinical and public health research on HIV in Switzerland 17,18 . The SHCS is a collaboration between various hospitals, clinics, laboratories, and private practices across the country. Prospective enrollment started in 1988, and involves PLWHIV aged 16 years or above. Detailed socio-demographic and behavioral parameters for each patient are collected at enrollment. Laboratory results such as CD4+ and CD8+ cell count, HIV-1 RNA viral load or indicators of exposure to hepatitis B or C virus are recorded at enrollment and during follow-up visits. Detailed information on ART and other treatments, and of AIDS defining events are also collected at regular intervals. While NADM are recorded in the study, their ascertainment is incomplete.
Linkage to cancer registries Incident cancers in the SHCS were identified through linkage of SHCS records with the records of the Basel, Geneva, and Zurich cantonal cancer registries. At the time of the linkage, the data covered the period up to 2012 for Geneva and Zurich, and 2011 for Basel. Only SHCS participants registered in the areas covered by the three aforementioned cancer registries were included, representing about 65% of all participants. The linkage was done using privacy-preserving probabilistic record linkage 19, 20 . Briefly, we employed a three-party protocol, with the SHCS and cancer registries collecting confidential individual-level patient data and the Institute of Social and Preventive Medicine at University of Bern serving as the independent linkage center. The linkage center supplied purpose-written encryption software 21 that was used at SHCS centers and cancer registries to irreversibly encrypt personal identifying data (names, date of birth) using Bloom filters and calculate the similarity coefficients, which were then used to identify matching records at ISPM.
Cancers included in analyses
We supplemented the cancer cases reported in the SHCS by the cases identified through data linkage. We analyzed NADM classified according to the 10 th revision of the International Classification of Diseases (ICD-10) that were diagnosed in about 40 or more patients: malignant neoplasm of anus and anal canal (C21), malignant neoplasm of liver and intrahepatic bile ducts (C22, excludes malignant neoplasm of other and unspecified parts of biliary tract), malignant neoplasm of trachea, bronchus and lung (C33-34), and prostate cancer (C61). We did not include Hodgkin lymphoma because most cases had been diagnosed in the early years of cART, when CD8 counts and viral load measurements were often missing.
Standardized incidence ratios
We calculated standardized incidence ratios (SIRs) for each identified NADM by comparing the observed number of cancers among people with HIV with the expected number of occurrences, based on age-, sex-and period-specific rates for the Swiss population provided by the National Institute for Cancer Epidemiology and Registration (indirect standardization) 22 . We produced 95% confidence intervals (CI) for the SIRs assuming a Poisson distribution 23 .
Baseline and time-updated exposure variables
We assessed the effect of baseline and time-updated exposure variables in Cox regression models. Time-updated variables included CD4 cell count (cells/µL), CD8 cell count (cells/µL), CD4/CD8 ratio and HIV viral load (copies/mL). We updated the immunological and virological factors at the start of each month. Months with no CD4 cell count, CD8 cell count, or HIV viral load were interpolated by carrying forward or carrying back the closest measured value within 12 months, provided there was no change in cART and no diagnosis of cancer in the interval. Time-updated bacterial pneumonia was additionally considered for lung cancer: history of bacterial pneumonia changed from no to yes when pneumonia was diagnosed. Other variables included age, likely HIV transmission group (men having sex with men [MSM], intravenous drug users [IDU], other men, other women), current smoking at enrollment (yes, no), highest completed level of education (compulsory, secondary, tertiary), chronic hepatitis B and exposure to hepatitis C (yes or no, as a time-updated variable), and calendar period (time-updated; before 2002, [2002] [2003] [2004] [2005] [2006] [2007] 2008 and later). Patients were defined as having chronic hepatitis B if they had previously been tested positive for HBs-antigen or HBV-DNA, and as being exposed to hepatitis C during follow-up if they had tested positive for HCV-RNA.
Statistical analyses
We used Cox regression models for time to event analyses, measuring time from enrollment to the diagnosis of a NADM, the last clinic visit in the study period, or death, whichever came first. Follow-up time in patients enrolled before 1996, the year cART was introduced, was left truncated at 31 December 1995. Patients diagnosed with a NADM before 1 January 1996 were excluded from the analysis for that specific NADM.
In a first step, we modeled the association of the time-updated immunological and virological exposure variables (CD4 cell count, CD8 cell count, CD4/CD8 ratio, and HIV viral load) with each of the four cancers separately, adjusting for the other variables. To reduce the risk of detecting associations that reflect reverse causality, we lagged these variables for 12 months or more, and captured cumulative exposure using simple moving averages (SMA). We entered the following representations of each variable: lagged by 12, 24 or 36 months; SMA over 12 months -lagged by 12 or 24 months; SMA over 24 months -lagged by 12 months (see Figure 1 ). In a next step we selected variables and representations of variables for inclusion into a final, malignancy-specific model. We selected one representation of each immunological and virological variable based on the goodness of fit (indexed by the Akaike information criteria [AIC]) and carried over variables significantly associated with cancer incidence (P <0.05) when modeled separately. The intermediary and final models were adjusted for the variables age, transmission group, smoking, education, chronic hepatitis B, exposure to hepatitis C, and calendar period. The time-updated variables for bacterial pneumonia (used only in the lung cancer analysis), hepatitis B, and hepatitis C were lagged by 12 months.
We assessed proportionality assumptions of the Cox model using the Schoenfeld residuals. Results are shown as hazard ratios (HR) with 95% confidence intervals (95% CI). We imputed missing values for smoking using multivariate imputation by chained equations and pooled results of five imputed dataset. We present the analyses with imputation since results were similar to complete-case analyses. All analyses were done in R Project for Statistical Computing (version 3.6.0) software 24 using packages survival (version 2.42), mice (version 3.30) and mitools (version 2.3). R code and explanatory documents are available as extended data 25 .
Results
Incidence and patient characteristics
A total of 563 incident NADM were identified in the two data sources (SHCS and cancer registries). The SHCS recorded 60.9% of all cases, and the registries 76.2%. For the cancers analyzed in this study, the completeness of recording of cases in the SHCS was 54.3% for anal cancer, 66.7% for liver cancer, 71.4% for lung cancer, and 72.7% for prostate cancer. The corresponding percentages for the cancer registries were 85.7%, 80.6%, 85.7% and 93.2%, respectively (Table 1) .
Anal cancer was diagnosed in 70 patients over 71,592 personyears for an incidence rate of 9.78 per 10,000 person-years (95% confidence interval [CI] 7.62-12.35). Lung cancer was diagnosed in 49 patients over 71,888 person-years (6.82 per 10,000; 95% CI 5.04-9.01), prostate cancer in 44 men over 50,322 person-years (8.74 per 10,000; 95% CI 6.35-11.74), and liver cancer in 36 patients over 71,911 person-years (5.01 per 10,000; 95% CI 3.51-6.93).
Compared to the Swiss general population, anal, lung, and liver cancer all exhibited higher rates in the SHCS, whereas the rate of prostate cancer was similar ( Figure 2 ). The difference was largest for anal cancer: the incidence was 76 times higher in people with HIV (SIR 76.1, 95% CI 60.2-96.2) than in the general Swiss population.
Characteristics of SHCS participants who developed cancer and participants who did not are shown in Table 2 . Compared to those who remained free of cancer, HIV-positive individuals, who developed cancer were slightly older, more likely to be smokers, and at a more advanced clinical stage of HIV infection according to the Centers for Disease Control and Prevention classification 26 . The distribution across HIV transmission groups also varied between cancers: the majority of patients who developed anal or prostate cancer were MSM, while those with lung or liver cancer were predominantly patients with a history of IDU.
Immunological and socio-behavioral risk factors
We selected one representation of each exposure variable based on goodness of fit models. The AIC values for the different models are shown in Table 3 , the results of the separate models for each immunological and virological variable in Table 4 and the results of the mutually adjusted models in Table 5 . For anal cancer, CD4 count, CD8 count and CD4/CD8 ratio were all associated with cancer risk in the separate models (Table 4 ). In the mutually adjusted model, a higher CD4 cell count (lagged 12 months) and a CD8 count below 1000 cells/µl (lagged by 24 months) continued to be significantly associated (P=0.002) with a reduced risk of anal cancer (Table 5 ). For example, in patients with a 12-month lagged CD4 count above 500 cells/µl, risk was reduced to about a fourth compared to individuals with a CD4 count below 200 cells/µl (hazard ratio [HR] 0.24; 95% CI 0.10-0.61). The risk of anal cancer was substantially higher in MSM (HR 6.86, 95% CI 1.64-28.6) than other men and higher in smokers (HR 2.07, 95% CI 1.07-3.98) compared to non-smokers. For lung cancer and prostate cancer, Cox regression models were stratified by age to preserve proportional hazards. In the case of lung cancer, CD8 cell count (lagged by 36 months) was the only significant predictor (P=0.04) among the immunological and virological variables ( Table 2) : participants with CD8 cell counts equal to or above 1000 cells/µl had a greater risk of developing lung cancer, compared to those with counts below 1000 cells/µl (HR 1.89, 95% CI 1.03-3.48). A history of bacterial pneumonia was associated with lung cancer in the separate model (Table 4 ), but not after adjusting for CD8 cell count (Table 5 ). Smoking at enrollment was strongly associated with lung cancer (HR 6.50, 95% CI 1.36-31.2, Table 5 ). For prostate cancer, none of the immunological or virological were associated with a risk of cancer (Table 4) , though there was some evidence of smoking being associated with higher rates (HR 1.92, 95% CI 0.96-3.83, Table 5 ).
For liver cancer, exposure to lower CD4 counts (SMA over 24 months, lagged by 12 months) and the CD4/CD8 ratio (lagged by 24 months) were associated with cancer incidence in the separate models (Table 4 ). In the final model (Table 5) , only the CD4 cell count was predictive, with patients with average counts of 500 cells/µl or above at much lower risk than patients with counts below 200 cells/µL (HR 0.07, 95% CI 0.01-0.59). Chronic hepatitis B infection (HR 7.86, 95% CI 3.78-16.4) and hepatitis C infection (HR 4.77, 95% CI 1.80-12.7) were both strongly associated with liver cancer (Table 5 ).
Discussion
In the era of cART, life expectancy of PLWHIV is approaching that of the general population, the incidence of AIDS-defining malignancies has declined sharply, and NADM have emerged as an important co-morbidity 1, 2, 27, 28 . This study linked the database of the SHCS with three cantonal cancer registries to identify incident NADM. Anal, lung, prostate and liver cancers were common NADM among participants of SHCS. Compared to the general population, three of the four cancers occurred more frequently among PLWHIV. The exception was prostate cancer, whose incidence was similar to the general population. Associations of lagged and cumulative exposure to immunodeficiency or immune senescence were evident for some but not all cancers, and HIV replication was not related to cancer risk. a risk factor for anal cancer, and excessive alcohol consumption for liver cancer, but data on sexual behavior and alcohol have been collected in the SHCS only since 2000 and 2005, respectively, and were not considered here.
The reasons for the higher cancer incidence in PLWHIV differ across cancers, and include multiple factors. Several studies have shown that immunodeficiency was associated with a higher risk of NADM 28, [33] [34] [35] . Some of these studies analyzed NADM as a single group, or as groups of infection-related and non-infection-related NADM. We found that immunodeficiency (indexed by exposure to low CD4 counts) was associated with anal cancer and liver cancer, but not with lung cancer or prostate cancer. Our results indicate that each NADM should be analyzed separately, rather than combining different NADM into groups.
For lung cancer, a high CD8 cell count several years prior to the diagnosis was a risk factor whereas a low CD4 count was not associated with lung cancer. Persistent CD8 cell elevation among HIV patients on long-term cART, a marker of immune senescence, is associated with inflammatory, non-AIDS related events such as cardiovascular, renal, respiratory, metabolic diseases and NADM, and with increased non-AIDS-related mortality [36] [37] [38] . Mussini and colleagues suggested that the CD4/ CD8 ratio might be a more robust marker of the immune dysfunction associated with NADM than the CD4 or the CD8 cell count 39 . Indeed, a study of US veterans living with HIV found that the CD4/CD8 ratio was the strongest predictor of incidence with CD4/CD8 ratio ratios below 1.0 associated with higher risk 15 . In contrast to the veterans study, the CD8 cell count was more robustly associated with lung cancer risk than either the CD4 cell count or the CD4/CD8 ratio in our analysis, suggesting that in the cART era, immune senescence rather than immunodeficiency increases the risk of lung cancer.
A history of recurrent pneumonia was associated with lung cancer risk in the HIV/AIDS Cancer Match study 40 and in the US Veterans Aging Cohort Study 15 . In our analyses, the timeupdated history of bacterial pneumonia was associated with lung cancer risk in the model adjusted for baseline variables, but evidence of this association disappeared after adjusting for CD8 count. Clearly, the most important risk factor for lung cancer is smoking, which in Switzerland and elsewhere is substantially more common among PLWHIV than in the general population [41] [42] [43] .
Smoking was also associated with anal cancer, but it remains unclear whether the association is causal or whether smoking is a marker for unsafe sexual behavior and exposure to HPV. Several studies have found that smoking may be associated with a higher risk of HPV infection [44] [45] [46] .
Prostate cancer is one of the most common malignancies among men in Western populations, and an important cause of cancer death. Older age, a positive family history, black race and elevated levels of insulin growth factor (IGF)-I have been shown to be risk factors for prostate cancer 47, 48 . Our results do not suggest that immunodeficiency or immune senescence strongly influence prostate cancer risk. In this context, it is noteworthy that prostate cancer is not consistently responsive to immune therapy, in contrast to other solid tumors, including lung cancer 49 .
Liver cancer was associated with prolonged exposure to CD4 counts below 500 cells/µl however; chronic viral hepatitis was a likely cause in almost all patients developing liver cancer: there was evidence of chronic HBV or HCV infection in 83% of patients with liver cancer. HBV and HCV were both strong risk factors for the cancer. An explanation for the strong association with HBV might be hepatitis delta virus (HDV) co-infection, which in the SHCS is observed in about 15% of patients with chronic HBV infection 50 . HDV infection accelerates the progression of HBV related liver disease, including hepatocellular cancer 50 .
Immunodeficiency and, to a lesser extent, immune senescence are prevented by starting cART as soon as possible after HIV diagnosis 36 , as recommended by the World Health Organization 51 . The "Universal Test and Treat" approach to HIV coupled with interventions to ensure adherence will likely reduce the incidence of some NADM. The integration of smoking cessation interventions into routine care of people living with HIV is another important measure 52 . All SHCS participants are tested for chronic HBV infection to guide decisions on HBV vaccination and on the inclusion antiretrovirals with activity against HBV in cART regimens, as recommended by guidelines 53, 54 . Similarly, testing for antibodies against HCV is done at HIV diagnosis and annually thereafter, and there is universal access to direct acting anti-virus (DAA) therapy against HCV. Future analyses of the incidence of NADM in the SHCS will document the impact of these measures. Of note, the effectiveness of anal cancer screening is unclear: the ongoing Anal Cancer/ HSIL Outcomes Research Study (ANCHOR) aims to determine whether treatment of high grade squamous intraepithelial lesions (HSIL) prevents anal cancer 55 .
Conclusions
The importance of immunodeficiency and immune senescence, and of other risk factors differs across NADM, with important implications for prevention. Immunodeficiency was an important risk factor for anal and liver cancer whereas immune senescence was associated with lung cancer and anal cancer.
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Non-AIDs cancers seem to be more frequent in well-treated patients on ART than the general population, due either to HIV persistent immune damage vs. lifestyle, behaviour risk or both. To prove this link, HIV infected persons should be compared to age matched general population in a relatively large population as the events remain encouragingly relatively low, during the ART era, where viral replication is controlled over long periods of time.
To this end, investigators from the well-established HIV Swiss cohort calculated standardized incidence ratios for each identified NADM by comparing the observed number of cancers with the expected number of occurrences. An indirect standardization was performed using period-specific rates for the Swiss population provided by the National Institute for Cancer Epidemiology and Registration using age and sex as co-variables. Influence of CD4 and CD8 count, CD4/CD8 ratio, and HIV viral load was assessed by Cox regression models. Higher rates of HPV driven anal (SIR 76.1, 95% Confidence interval (CI) 60.2-96.2), lung (SIR 1.98, 1.50-2.62), and liver cancer (SIR 7.28, 5.25-10.1) were observed. Hormonally driven cancer like prostate cancer was similar in HIV and control population (SIR 1.03, 0.76-1.38). Interestingly, anal cancer was associated with low CD4, with high CD8, and smoking. Interestingly, for lung cancer, CD8 cell count was the only predictor identified opening new hypothesis on inflammation in the context of ART-treated persons. As expected, CD4 cell count and chronic hepatitis B and C infection were predictive of liver cancer incidence.
Several issues should be addressed: Types of cancer should be divided into viral-related and those not known to be associated with viruses like lung and prostate.
Focus should be on lung cancer and its relationship with CD8 and nadir CD4 T cell if data available.
Effort should be on novelty and not confirming previous data.
Changes occurring or not in cancer incidence during the study period should be highlighted.
Discussion on Cd8 elevation and occurrence of lung cancer should be more detailed as future direction for research.
Conclusion:
Immunodeficiency was an important risk factor for anal and liver cancer, whereas immune senescence was associated with lung cancer and anal cancer. I think anal cancer with immune senescence should be removed from the conclusion as it seems to be more driven by CD4 T cells and the conclusion is not clear. Findings of lung cancer and immune senescence are the novelty of this manuscript and open several hypothesis including smoking and CD8 elevation in non-HIV population and immune senescence linked with CMV serostatus.
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